Symbiomix developed the first oral, single dose treatment in the United States for bacterial vaginosis (BV), a common gynecological infection that increases the risk of serious health problems. Symbiomix was acquired by Lupin Pharmaceuticals. Learn more at www.symbiomix.com.
Location: United States, New Jersey, Newark
Employees: 51-200
Total raised: $41M
Founded date: 2012
Investors 2
| Date | Name | Website |
| - | F-Prime Ca... | fprimecapi... |
| - | Eight Road... | eightroads... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 06.05.2015 | Series A | $41M | - |
Mentions in press and media 4
| Date | Title | Description |
| 07.05.2015 | Symbiomix Therapeutics closes $41M Series A | With a third infusion of investment, Symbiomix Therapeutics closed a $41 million Series A round, the company announced Wednesday. Symbiomix, which is working to bring a single-dose treatment for bacterial vaginosis to market, also reported ... |
| 06.05.2015 | Symbiomix Therapeutics Lands $41M Financing | NEWARK, NJ, Symbiomix Therapeutics today announced multiple milestones, including the closing of the third and final tranche of a $41 million Series A financing. >> Click here for more funding data on Symbiomix Therapeutics >&g... |
| 06.05.2015 | Symbiomix Therapeutics Closes $41M Series A Financing | Symbiomix Therapeutics, a Newark, N.J.-based late-stage, privately held biopharmaceutical company, closed the third and final tranche of a $41m Series A financing. Investors included OrbiMed, Fidelity BioSciences, and HBM Partners, as well ... |
| 09.03.2015 | Symbiomix Therapeutics is working on a single-dose treatment for bacterial vaginosis | Bacterial vaginosis (BV) infects about 20 million women in the U.S. every year. As a result of contracting the gynecological disease, those women have an increased chance of contracting sexually transmitted diseases and spreading HIV. “It’s... |